Navigation Links
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Date:3/7/2012

LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

"I am excited that our scientific findings will help save lives," said Charles Cochrane, MD, professor emeritus at Scripps Research. "Many years of work in our basic research laboratory at The Scripps Research Institute made this landmark development possible."

Respiratory distress syndrome (also known as neonatal respiratory distress syndrome) is a life-threatening condition affecting pre-term infants. The more premature an infant is, the more likely he or she is to suffer from it and die.

The condition occurs when infants are born prior to the time when natural surfactant is made in their lungs. Surfactant is a liquid that coats the inside of the lungs, helping to keep the air sacs open and making normal breathing possible. Without enough surfactant, the lungs collapse and the body can be starved of oxygen.

In addition to mechanical ventilation, current treatments for pre-term infants involve using surfactants derived from chopped cow or pig lungs. However, animal-derived surfactants are expensive, contain material that can be injurious to the lungs, and cannot be produced in quantities sufficient to treat pre-term infants worldwide. In addition, animal-derived surfactants can only be used once since they cause an immune reaction; in contrast, the new synthetic surfactant is not immunogenic.

The Cochrane lab first created a synthetic version of surfactant in the 1990s, mimicking a natural peptide known as Surfactant Protein B; the inventors of the technology are Cochrane and Susan Revak. After this formative work at Scripps Research, the therapy was developed by Discovery Labs of Warrington, PA, which oversaw the three phases of clinical trials required by the FDA. These clinic trials provided data on the drug's success.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
(Date:3/13/2020)... ... March 13, 2020 , ... Cryo-Cell International’s announcement is ... performed by Dr. Hal Boxmeyer and colleagues, which determined sample viability of 23.5 ... under proper conditions. Cryo-Cell International marks the first family cord blood bank to ...
(Date:3/11/2020)... , ... March 11, 2020 , ... ... telemedicine company backed by Siemens Healthineers and several healthcare VC firms introduces a ... 100,000 people in over 100 countries and has caused over 4,000 fatalities to ...
(Date:3/9/2020)... ... March 09, 2020 , ... ... 64% last year, as enterprises sought to achieve competitive advantage by transforming ... 13% of all transformation efforts delivered the intended consequences. , Application transformation ...
Breaking Biology News(10 mins):
(Date:3/3/2020)... ... March 03, 2020 , ... Frictionless Solutions, a specialized event ... was recognized by INC. 5,000 on an annual list of America’s fastest growing ... greatly impacting their spheres of influence and experiencing considerable development. INC. 5,000’s specific ...
(Date:2/26/2020)... ... 25, 2020 , ... Continuing its leading research on human ... its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. , 3-FL ... carbohydrates are indigestible and therefore function as a prebiotic by promoting early microbial ...
(Date:2/21/2020)... (PRWEB) , ... February 21, 2020 , ... Join Forrest ... Southeast Region of Sequence, Inc. for an informative session on ... Design Flexibility: Key elements to incorporate into facility design to add manufacturing flexibility ...
(Date:2/19/2020)... ... February 19, 2020 , ... Red Nucleus, ... sciences industry, today announced the opening of a new office in Tokyo, Japan. ... R&D. , Red Nucleus announced the new office in response to customer requests ...
Breaking Biology Technology: